PhaseRx Inc
PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder program… Read more
PhaseRx Inc (PZRXQ) - Net Assets
Latest net assets as of September 2017: $-301.00K USD
Based on the latest financial reports, PhaseRx Inc (PZRXQ) has net assets worth $-301.00K USD as of September 2017.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.04 Million) and total liabilities ($6.34 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-301.00K |
| % of Total Assets | -4.99% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
PhaseRx Inc - Net Assets Trend (2014–2016)
This chart illustrates how PhaseRx Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PhaseRx Inc (2014–2016)
The table below shows the annual net assets of PhaseRx Inc from 2014 to 2016.
| Year | Net Assets | Change |
|---|---|---|
| 2016-12-31 | $9.30 Million | +119.02% |
| 2015-12-31 | $-48.89 Million | -17.70% |
| 2014-12-31 | $-41.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to PhaseRx Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2751400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2016)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.01% |
| Other Comprehensive Income | $3.00K | 0.03% |
| Other Components | $78.77 Million | 847.29% |
| Total Equity | $9.30 Million | 100.00% |
PhaseRx Inc Competitors by Market Cap
The table below lists competitors of PhaseRx Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ACTIVEX
BE:A4T
|
$1.02K |
|
Tristar Wellness
PINK:TWSI
|
$1.02K |
|
WATER RES GRP
BE:WXV
|
$1.02K |
|
Alveen
PA:MLALV
|
$1.02K |
|
Arete Industries Inc
PINK:ARET
|
$1.02K |
|
Imagin Medical Inc
PINK:IMEXF
|
$1.02K |
|
Optigis S.A.
WAR:OPI
|
$1.01K |
|
Finseta Plc
LSE:FIN
|
$1.01K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PhaseRx Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2015 to 2016, total equity changed from -48,889,000 to 9,297,000, a change of 58,186,000.
- Net loss of 20,137,000 reduced equity.
- Share repurchases of 18,500,000 reduced equity.
- Other comprehensive income increased equity by 3,000.
- Other factors increased equity by 96,820,000.
Equity Change Factors (2015 to 2016)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-20.14 Million | -216.6% |
| Share Repurchases | $18.50 Million | -198.99% |
| Other Comprehensive Income | $3.00K | +0.03% |
| Other Changes | $96.82 Million | +1041.41% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares PhaseRx Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $-7.05 | $0.00 | x |
| 2015-12-31 | $-6.20 | $0.00 | x |
| 2016-12-31 | $1.24 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PhaseRx Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -216.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.77x
- Recent ROE (-216.60%) is below the historical average (-72.20%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | -570.75% | 0.45x | 0.00x | $-2.70 Million |
| 2015 | 0.00% | -1967.20% | 0.10x | 0.00x | $-2.49 Million |
| 2016 | -216.60% | 0.00% | 0.00x | 1.77x | $-21.07 Million |
Industry Comparison
This section compares PhaseRx Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PhaseRx Inc (PZRXQ) | $-301.00K | 0.00% | N/A | $1.02K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |